Home › Compare › INNMF vs GBDC

INNMF vs GBDC: Dividend Comparison 2026

INNMF yields 1081.08% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INNMF wins by $37306267.33M in total portfolio value
10 years
INNMF
INNMF
● Live price
1081.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37306288.18M
Annual income
$31,563,031,594,132.85
Full INNMF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — INNMF vs GBDC

📍 INNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINNMFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INNMF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
INNMF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INNMF
Annual income on $10K today (after 15% tax)
$91,891.89/yr
After 10yr DRIP, annual income (after tax)
$26,828,576,855,012.92/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, INNMF beats the other by $26,828,562,871,889.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INNMF + GBDC for your $10,000?

INNMF: 50%GBDC: 50%
100% GBDC50/50100% INNMF
Portfolio after 10yr
$18653154.52M
Annual income
$15,781,524,022,433.34/yr
Blended yield
84.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

INNMF
No analyst data
Altman Z
45.4
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INNMF buys
0
GBDC buys
0
No recent congressional trades found for INNMF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINNMFGBDC
Forward yield1081.08% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$37306288.18M ✓$20.85M
Annual income after 10y$31,563,031,594,132.85 ✓$16,450,733.83
Total dividends collected$36872092.59M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: INNMF vs GBDC ($10,000, DRIP)

YearINNMF PortfolioINNMF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$118,808$108,108.11$12,492$1,791.70+$106.3K → INNMF
2$1,327,510$1,200,385.03$16,527$3,160.58+$1.31M → INNMF
3$13,955,553$12,535,117.70$23,588$5,904.90+$13.93M → INNMF
4$138,087,992$123,155,549.73$37,141$11,901.65+$138.05M → INNMF
5$1,286,637,044$1,138,882,892.71$66,205$26,463.38+$1286.57M → INNMF
6$11,294,046,827$9,917,345,190.59$137,452$66,612.65+$11293.91M → INNMF
7$93,443,552,038$81,358,921,932.82$342,372$195,298.53+$93443.21M → INNMF
8$729,086,740,275$629,102,139,594.15$1,053,292$686,954.33+$729085.69M → INNMF
9$5,367,529,524,068$4,587,406,711,974.06$4,111,439$2,984,416.95+$5367525.41M → INNMF
10$37,306,288,184,886$31,563,031,594,132.85$20,849,974$16,450,733.83+$37306267.33M → INNMF

INNMF vs GBDC: Complete Analysis 2026

INNMF — Stock

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full INNMF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this INNMF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INNMF vs SCHDINNMF vs JEPIINNMF vs OINNMF vs KOINNMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.